Literature DB >> 20652840

Comorbidities in patients with persistent or chronic immune thrombocytopenia.

Cheryl Enger1, Dimitri Bennett, Ulla Forssen, Patrick F Fogarty, Andrew T McAfee.   

Abstract

There is a paucity of epidemiological data on the risk of comorbidities in adults with persistent or chronic immune thrombocytopenia (ITP). In this study, we compared the rates of cataracts, diabetes, renal failure, vascular events, lymphoma, and leukemia among patients with and without persistent or chronic ITP. Using administrative data, adult patients with medical claims for ITP from January, 2000 through September, 2006 were identified. An age- and gender-matched comparison cohort without evidence of ITP was randomly selected. The incidence rate ratio (IRR) of each comorbidity among ITP patients relative to the comparison group was estimated using Poisson regression, adjusting for baseline covariates. A total of 3,131 patients with persistent or chronic ITP were identified, and 9,392 were selected for the comparison cohort. The adjusted IRRs were as follows: diabetes 1.73 (95% CI 1.36-2.20), renal failure 2.05 (95% CI 1.67-2.51), any vascular event 1.70 (95% CI 1.41-2.05), lymphoma 5.91 (95% CI 2.61-13.37), leukemia 19.83 (95% CI 5.84-67.34), and mortality 4.21 (95% CI 3.06-5.79). There was no increased risk for cataract or myocardial infarction in the ITP cohort. Patients with persistent or chronic ITP are at increased risk for several comorbidities including hematologic malignancies, relative to a matched comparison cohort.

Entities:  

Mesh:

Year:  2010        PMID: 20652840     DOI: 10.1007/s12185-010-0636-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  9 in total

Review 1.  Immune thrombocytopenic purpura.

Authors:  Douglas B Cines; Victor S Blanchette
Journal:  N Engl J Med       Date:  2002-03-28       Impact factor: 91.245

2.  Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal.

Authors:  M A Feudjo-Tepie; N J Robinson; D Bennett
Journal:  J Thromb Haemost       Date:  2008-01-21       Impact factor: 5.824

3.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

4.  Guidelines for good pharmacoepidemiology practices (GPP).

Authors: 
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-02       Impact factor: 2.890

5.  Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia.

Authors:  Ola Landgren; Eric A Engels; Ruth M Pfeiffer; Gloria Gridley; Lene Mellemkjaer; Jørgen H Olsen; Kimberly F Kerstann; William Wheeler; Kari Hemminki; Martha S Linet; Lynn R Goldin
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

6.  Prevalence of immune thrombocytopenia: analyses of administrative data.

Authors:  J B Segal; N R Powe
Journal:  J Thromb Haemost       Date:  2006-07-27       Impact factor: 5.824

7.  Risk of cataract among idiopathic thrombocytopenic purpura patients in the UK general practice research database.

Authors:  Maurille A Feudjo-Tepie; Susan A Hall; John Logie; Noah J Robinson
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-05       Impact factor: 2.890

8.  Accuracy of identification of patients with immune thrombocytopenic purpura through administrative records: a data validation study.

Authors:  Jodi B Segal; Neil R Powe
Journal:  Am J Hematol       Date:  2004-01       Impact factor: 10.047

9.  Comorbidities of idiopathic thrombocytopenic purpura: a population-based study.

Authors:  M A Feudjo-Tepie; G Le Roux; K J Beach; D Bennett; N J Robinson
Journal:  Adv Hematol       Date:  2009-04-02
  9 in total
  9 in total

1.  Management of myocardial infarction in immune thrombocytopenic purpura with anti-phospholipid antibodies.

Authors:  Rie Tabata; Chiharu Tabata; Yoshio Kita
Journal:  J Thromb Thrombolysis       Date:  2013-01       Impact factor: 2.300

2.  Is Autoimmune Thrombocytopenia Itself the Primary Disease in the Presence of Second Diseases Data from a Long-Term Observation.

Authors:  Nasra Aboud; Fabian Depré; Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2016-10-18       Impact factor: 3.747

Review 3.  Splenectomy for immune thrombocytopenia: down but not out.

Authors:  Shruti Chaturvedi; Donald M Arnold; Keith R McCrae
Journal:  Blood       Date:  2018-01-02       Impact factor: 22.113

4.  Thromboembolism in patients with immune thrombocytopenia (ITP): a meta-analysis of observational studies.

Authors:  Wendy J Langeberg; W Marieke Schoonen; Melissa Eisen; Laurence Gamelin; Scott Stryker
Journal:  Int J Hematol       Date:  2016-03-24       Impact factor: 2.490

5.  Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim.

Authors:  Douglas B Cines; Terry Gernsheimer; Jeffrey Wasser; Bertrand Godeau; Drew Provan; Roger Lyons; Ivy Altomare; Xuena Wang; Angela Lopez
Journal:  Int J Hematol       Date:  2015-07-23       Impact factor: 2.490

6.  The presence of idiopathic thrombocytopenic purpura and incidence of acute non-ST elevation myocardial infarction.

Authors:  Mitchell Davis; Mohammad Reza Movahed; Mehrtash Hashemzadeh; Mehrnoosh Hashemzadeh
Journal:  Ann Hematol       Date:  2021-10-01       Impact factor: 3.673

7.  Ischemic stroke/transient ischemic attack in adults with primary immune thrombocytopenia: a meta-analysis.

Authors:  Lishou Pan; Huilin Leng; Yin Huang; Ningyan Xia; Lingjin Jin; Han-Ting Zhang
Journal:  Neurol Sci       Date:  2020-10-02       Impact factor: 3.307

8.  Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia.

Authors:  Soames Boyle; Richard H White; Ann Brunson; Ted Wun
Journal:  Blood       Date:  2013-05-01       Impact factor: 22.113

Review 9.  Thrombopoietin receptor agonists: ten years later.

Authors:  Waleed Ghanima; Nichola Cooper; Francesco Rodeghiero; Bertrand Godeau; James B Bussel
Journal:  Haematologica       Date:  2019-05-09       Impact factor: 9.941

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.